Eli Lilly (LLY) announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of EBGLYSS in pediatric patients with moderate-to-severe atopic dermatitis
Importance
Level 1
#ELI LILLY & CO#LLY.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#GLOBAL NEWS#US EQUITIES